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Summary 
Plasminogen activation by urokinase-type plasminogen activator (uP A) is 
implicated in tumor invasion and metastasis by the breakdown of extracellular matrix. 
We have recently demonstrated the inhibitory effect of cAMP on uP A gene 
transcription in RC-K8 human lymphoma cells. Prostacyclin produced by endothelial 
cells is shown to increase cellular cAMP levels by activating adenylate cyclase. We, 
therefore, examined the effect of a stable analogue of prostacyclin, Beraprost, on uP A 
production in RC-K8 cells. uP A activity gradually increased in the conditioned medium 
with time. Beraprost (0.1 nM -1.0 ,uM) inhibited uP A accumulation in a dose-dependent 
manner without affecting cell viability. High and low molecular forms of uP A were 
present in the conditioned medium, but no PA inhibitor was demonstrated by fibrin 
zymography. All forms of uP A decreased after Beraprost-treatment. Northern blot 
analysis revealed that after exposure to Beraprost, uP A mRNA levels increased 
transiently and then rapidly decreased to below control levels. Treatment with 
Beraprost resulted in a rapid activation of cellular cyclic AMP-dependent protein 
kinase (PKA). Beraprost completely negated uP A gene expression induced by phorbol 
myristate acetate, an activator of protein kinase C (PKC). These results suggest that 
Beraprost inhibits uP A production by suppressing uP A gene expression may be through 
the PKA pathway and that PKA-mediated signals are dominant in uP A gene expression 
as compared to those medicated by PKC. This inhibition of uP A expression by a 
prostacyclin analogue may be an important fact to explain the mechanism of 
antimetastatic effects of prostacyclin. 
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Introduction 
Invasion and metastasis are the main cli nical characteristics of malignant 
tumors. uP A is one of the tumor-associated proteases and strongly involved in tumor 
cell invasion and metastasis. The invasiveness and metastatic potential appear to 
correlate with the PA activity on cell surface; uP A receptors expressed on the cell 
surface localize uP A to cell-cell and cell-substratum contact sites (1-3). A number of 
studies have reported this involvement in malignant tumors, for example, colorectal 
cancer ( 4, 5), gastric cancer (6, 7), breast cancer (8), lung cancer (9), and so on. 
Especially, tumor invasion into vascular endothelium is an indispensable step of 
metastasis and, therefore, endothelium is thought to be a barrier of tumor cell invasion. 
It has been shown that prostacyclin, derived from cyclooxygenase pathway of 
arachidonic acid metabolism in vascular endothelial cells, activates adenylate cyclase 
and increases cAMP levels (1 0, 11) and that prostacyclin acts not only as an antagonist 
of platelet aggregation (12) but also as a vasodilator via the PKA pathway (13, 14). In 
addition, a number of experiments have demonstrated the antimetastatic effects of 
prostacyclin and its analogues in vitro and in vivo (15, 16). Mechanistic studies 
revealed that the antimetastatic effects of prosacyclin and its analogues are more related 
to their interference with tumor cell-host interactions (such as tumor cell induced 
platelet aggregation, tumor cell adhesion to endothelial cells and subendothelial matrix, 
tumor cell induced endothelial cell retention, etc . .) than their direct inhibition of the 
growth of primary tumors. However, there is no report refers to the effect of 
prostacyclin on uP A production in tumor cells so far. 
RC-K8 is a human pre-B lymphoma cell line which constantly produces uP A in 
conditioned medium (17), and RC-K8 cells produce massive metastatic tumors in the 
lungs when injected intraperitoneally into immunosuppressed newborn hamsters (18). 
We found that a PKC activator, phorbol myristate acetate (PMA), stimulates uP A 
production in RC-K8 cells (17), whereas cAMP inhibits uP A production through the 
PKA pathway (19), although previous studies from other groups have generally 
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reported that cAMP has a stimulatory effect on uP A. production (20-23). Therefore, we 
examined whether a stable prostacyclin analogue, Beraprost, induces PKA activation 
and inhibits uP A production in RC-K8 cells. The effect of Beraprost on PMA-induced 
uP A gene expression was also examined in this paper. 
Materials and Methods 
Reagents 
Beraprost was a generous gift of Kaketsukenn (Kumamoto, Japan). 3- [ 4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MIT) was purchased from 
Sigma Chemicals (St. Louis, MO, USA). A random primed labeling kit was form 
Boehringer Mannheim Biochemica (Mannheim, Germany). 
Cell culture and Cell Growth Studies 
RC-K8 and PL-21 cells were grown in RPMI-1640 culture medium 
supplemented with 10 % heat-inactivated fetal bovine serum (FBS, Whittaker 
Bioproducts, Walkersville, MD USA), 100 U/mL penicillin, and 100 ,Ug/mL 
streptomycin as previously described (17, 24). To examine the effect of Bcraprost on 
uP A production, cells were cultured for 48 h in serum-free RPMI-1640 medium 
containing various concentrations (0.1 nM -1 .uM) of Beraprost. Every experiment was 
performed in triplicate. Cell viability was detennined by trypan blue dye exclusion 
under bright-field microscopy . The number of surviving and proliferating cells was 
measured by the colorimetric MIT assay for mitochondrial dehydrogenase enzyme 
activity as described by Mosmann (25). The correlation curve between cell numbers, 
counted by the trypan blue dye exclusion method:, and the amount of MTT formazan 
generated was used to calculate the cell number. The assay was conducted with cells 
growing in 0.1 ml medium in triplicate. 
uP A activity 
uP A activity in conditioned medium was quantitatively measured using 
chromogenic substrate S-2444 (KABI Diagnostica, Stockholm, Sweden) (26). Briefly, 
the reaction was started by adding 50 p;L of S-2444 (1 mglml) to each well of a 96-well 
microplate containing 50 p;L test sample. Increases in absorbance at 405 nm over a 20-
min period were measured using a micro-ELISA-reader. The results were compared to 
those obtained using serially diluted standard uP A (The Green Cross, Osaka, Japan). 
SDS-PA GE and Fibrin-Zymography 
RC-K8 conditioned medium (20 p;L) mixed with electrophoresis buffer (0.1 M 
Tris HCl pH 6.8, 2% SDS, 20% glycerol) was incubated at 37oC for 2 h and then 
electrophoresed in 6-15 % lineal gradient polyacrilamide slab gel using the Laemmli's 
buffer system. After electrophoresis, SDS in the gel was removed by soaking in 2.5% 
Triton X-100 solution for 2 h and PA activity in the gel was visualized by fibrin­
zymography (27). 
RNA preparation and Northern blot analysis 
Total RNA was isolated by the acid guanidinium thiocyanate-phenol­
chloroform method (28). Total RNA (10 p;g) was subjected to Northern blot analysis as 
described (29). uP A eDNA ( 461 bp encoding amino acid residues 165-301, a gift of 
The Green Cross) and �actin eDNA (Wako Pure Chemicals, Osaka, Japan) were 
labeled with e2P]-dCTP (ICN Biomedicals, Irvine, CA, USA) by the random primer 
method. mRNA levels were quantitatively measured by counting radioactivity using the 
BAS 2000 Imaging analyzer (Fuji film, Tokyo, Japan) 
Detection and quantitation of PKA activity in RC-KB cells after stimulation with 
Beraprost 
PKA activity in cell lysates was measun�d using a non-radioactive method 
developed by Promega (Madison, WI, USA). After stimulation with Beraprost, cells 
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were washed with phosphate-buffered saline and resuspended in 100 ,ul of cell lysis 
buffer (Tris-HCl pH 7.5 150 mM, EDTA 0.5 mM, EGTA 0.5 mM, 2-mercaptoethanol 
10 mM, leupeptin 20 ,ug/mL, PMSF 0.5 mM and Triton X-100 0.5%). Reaction 
mixtures containing 10 ,uL of cell lysate, 5 ,uL ATP, 5 ,uL PepTag TM A1 peptide and 5 
,uL (5 x) reaction buffer were incubated for 30 min at 30°C. Phosphorylated peptides 
were separated from non-phosphorylated peptides by agarose gel electrophoresis 
according to the manufacturer's instructions. Protein kinase activities were quantified 
using a spectrofluorometer (Shimazu, Kyoto, Japan) as follows. Negatively-charged 
phosphorylated bands were excised from the gel and melted according to the 
manufacturer's instructions. Melted gels were diluted with 2.5 mL distilled water, and 
the intensity of the emission wavelength (592 nm) was measured using the 
spectrofluorometer. Due to the unreliability of the PKA standard included in the kit, 
absolute PKA levels in cell lysates could not calculated; therefore PKA activity was 
expressed as relative values. 
Statistical analysis 
Statistical analysis was done on a Macintosh Ilsi (Apple Computer, Inc., 
Cupertino, CA, USA). Results were expressed as rnean ± SE. Statistical significant was 
determined using the Student t-test to compare unpaired data. 
Results 
Effect of Beraprost on uP A accumulation in RC-KB conditioned medium 
Approximately 45 IU/mL uP A was accumulated in RC-K8 conditioned 
medium 48 h after replacement of culture medium ·with FBS-free RPMI-1640 medium. 
Beraprost inhibited uP A accumulation in a dose-dependent manner (Fig. 1) without 
affecting cell viability, checked by the MTT method. It was further confirmed by the 
fibrin-zymography as shown in Fig. 2. Although different sized PAs are present in the 
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conditioned medium, all of them belong to uP A since the PA activity was specifically 
inhibited by anti-uPA antiserum but not by anti-tissue-type PA antiserum (data not 
shown). Therefore, the smaller sized forms are thought to be degraded uP As, 
compatible to the low molecular forms of two chain uP As and the largest band 
coincided with the high molecular form of uP A (30). Neither PA inhibitor nor PA/PA 
inhibitor complex was present in RC-K8 conditioned medium. Beraprost itself showed 
no effect on uP A activity when directly mixed with the standard uP A or RC-K8 
conditioned medium. 
PKA activation by Beraprost 
We examined whether Beraprost actually induces PKA activation in RC-K8 
cells, because prostacyclin is known to be an activator of adenylate cyclase and 
increases cellular cAMP levels {10, 11). Beraprost certainly induced PKA activation in 
a dose- and time-dependent manner as shown in Fig. 3, panel A and B. We did not 
measure intracellular cAMP levels, but Beraprost must elevate cAMP levels through 
the adenylate cyclase pathway in RC-K8 cells. 
Northern blot analysis 
After treatment with Beraprost, uP A mRN.A levels transiently increased and 
then rapidly decreased below control levels (Fig. 4). This time-course is very similar to 
that induced by cAMP shown in our previous report (19). As well as PKA, PKC is an 
important effector molecule that controls uP A gene expression (31-33). We know that 
addition of PMA, a tumor promoter and PKC activator, to RC-K8 cell culture medium 
induces uP A production (17). Therefore, effect of Beraprost on PMA-induced uP A 
gene expression was also investigated. uP A mRNA levels significantly increased from 
2 to 9 hours after exposure to 1 ,uM PMA and the peak induction was observed after 5 
hours (data not shown). Interestingly, Beraprost cornpletely inhibited the PMA-induced 
uP A expression as shown in Fig. 5. 
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Discussion 
Our results clearly demonstrate the inhibitory effect of Bcraprost on uP A 
production in RC-K8 cells, supporting our previous findings; cAMP inhibits uP A 
expression via the PKA pathway (19). In addition, Beraprost partly inhibited uP A gene 
expression in 5 out of 6 esophageal carcinoma cell lines examined (data not shO\\'n). 
Therefore, this inhibitory effect of Beraprost on uP A gene expression seems to be not 
restricted in RC-K8 cells. However, it has been generally shown that cAMP has a 
stimulating effect on uP A production (20-23). The mechanism of cAMP-induced uP A 
gene expression in LLC-PK1 porcine kidney cells has been extensively investigated by 
Nagamine and coworkers, who have identified a cAMP-responsive region 3.4 kb 
upstream of the transcription initiation site (34 ). PKC as well as PKA plays an 
important role in cellular signal transduction. It has been also shown that uP A is 
induced upon the activation of PKC in a number of cells (17, 31-33), and it appears to 
be independent of PKA (31, 32, 35). Interestingly, Beraprost completely inhibited 
PMA-induced uP A expression, suggesting that cA1vfP-mediatcd signals are dominant in 
uP A gene expression as compared to those by PKC. Similar inhibitory effect of cAMP 
on PMA-induced uP A gene expression was also observed in human glomerular 
epithelial cells and the MOCK cells (32). As sho·wn in our previous report (19), the 
correlation between PKA activation and down-regulation of uP A production after 
cAMP stimulation suggests that phosphorylated factors by PKA are implicated in the 
down-regulation process. Recent studies have identified different isoforms of the 
cAMP-responsive element (CRE) binding protein. Among them, CREM isoforms 
appear to regulate CRE-mediated transcription both positively and negatively (36). 
Therefore, such CREM may act as a uP A gene expression inhibitor in RC-K8 cells. 
A number of experiments have demonstrated the antimetastatic effects of 
prostacyclin and its analogues in vitro and in vivo;; many mechanisms are proposed in 
the antimetastatic effects of prostacyclin, among which are direct anti-proliferation 
effect, inhibition of tumor cell-induced platelet aggregation and inhibition of tumor cell 
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adhesion to endothelial cells (15, 16). Ho\vever, there is no previous report refers to the 
effect of prostacyclin on uP A production in tumor cells so far. The inhibition of uP A 
expression by a prostacyclin analogue may be an important fact to explain the 
mechanism of anti metastatic effects of prostacyclin. Any way, vascular endothelium 
must function as a physical and biological barrier to tumor invasion and metastasis. As 
shown in our previous papers (37, 38), cAMP and PMA synergistically induce 
plasminogen activator inhibitor type 2 (PAI-2) expression in PL-21 human malignant 
cells. Beraprost virtually enhanced PMA-induced PAI-2 gene expression in PL-21 cells 
(data not shown). These results suggest that the stimulation which gives rise to an 
increase in cAMP levels appears to inhibit plasminogen activation in tumor cells and 
prevent the tumor cell infiltration and invasion. We know that RC-K8 cells express 
uP A receptors on the cell surface, checked by the flow cytometry using a monoclonal 
antibody against the uP A receptor, and produce massive metastatic lung tumors when 
injected into immuno-suppressive newborn hamsters (18). Further investigations will 
undoubtedly help our understanding of the role of uP A modulation by prostacyclin on 
tumor invasiveness and metastatic potential of this cell line. 
Acknowledgments 
This work was supported in part by Grants-in-Aid (No. 06671079) for 
Scientific Research (to K.N.) from the Ministry of Education, Science and Culture, 
Japan. We thank Naoko Ejiri for excellent technical assistance. 
Abbreviations 
Abbreviations used are: uP A, urokinase-type plasminogen activator; PKC, 
protein kinase C; PKA, cAMP-dependent protein kinase; PMA, phorbol myristate 
acetate; MTT, 3-[ 4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tctrazolium bromide; FBS, 
fetal bovine serum; CRE, cAMP-responsive element. 
9 
References 
1. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, 
Appella E, Blasi F. Cloning and expression of the receptor for human urokinase 
plasminogen activator, a central molecule in cell su:rface, plasmin dependent proteolysis 
[published erratum appears in EMBO J 1990 May;9(5):1674]. EMBO J 1990; 9: 467-
74. 
2. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: 
involvement in cell surface proteolysis and cancer invasion. [Review]. Ann NY Acad 
Sci 1992; 667: 13-31. 
3. Cro\vley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. 
Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci 
USA 1993; 90: 5021-5. 
4. Ganesh S, Sier C, Heerding MM, Griffioen G, Lamers C, Verspaget HW. 
Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-2. 
5. Wang H, Skibber J, Juarez J, Boyd D. Transcriptional activation of the 
urokinase receptor gene in invasive colon cancer. Int J Cancer 1994; 58: 650-7. 
6. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder 
JD, Fink U, Siewert JR. Prognostic impact of urokinase-type plasminogen activator and 
its inhibitor pai-l in completely resected gastric cancer. Cancer Res 1994; 54: 2900-7. 
7. Wang SN, Miyauchi M, Koshikawa N, �viaruyama K, Kubota T, Miura K, 
Kurosawa Y, Awaya A, Kanai Y. Antigen expression associated with lymph node 
metastasis in gastric adenocarcinomas. Pathology International 1994; 44: 844-9. 
10 
8. Duffy MJ, Reilly D, Mcdermott E, Ohiggins N, Fennelly JJ, Andreasen PA. 
Urokinase plasminogen activator as a prognostic marker in different subgroups of 
patients with breast cancer. Cancer 1994; 74: 2276-.SO. 
9. Pedersen H, Brunner N, Francis D, Ostcrlind K, Ronne E, Hansen HH, Dano 
K, Grondahlhansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 
plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer 
Res 1994; 54: 4671-5. 
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from 
arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits 
platelet aggregation. Nature 1976; 263: 663-5. 
11. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of 
prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti­
thrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-44. 
12. Moncada S, Korbut R, Bunting S, Vane JR. Prostacyclin is a circulating 
hormone. Nature 1978; 273: 767-8. 
13. Armstrong JM, Dusting GJ, Moncada S, Vane JR. Cardiovascular actions of 
prostacyclin (PGI2), a metabolite of arachidonic acid which is synthesized by blood 
vessels. Circ Res 1978; 43 (Supp. 1): 112-9. 
14. Kadowitz PJ, Chapnick BM, Feigen LP, I-lyman AL, Nelson PK, Spannhake 
EW. Pulmonary and systemic vasodilator effects of the newly discovered 
prostaglandin, PGI2. J Applied Physiol: Respiratory Environ Exercise Physiol 1978; 
45: 408-13. 
11 
15. Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an 
epiphenomenon. [Review]. Semin Thromb Hemost 1992; 18: 392-415. 
16. Schneider MR, Tang DG, Schirner M, Honn KV. Prostacyclin and its 
analogues: antimetastatic effects and mechanisms of action. [ Review]. Cancer 
Metastasis Rev 1994; 13: 349-64. 
17. Niiya K, Nsimba M, Hayashi T, Sakuraga,.va N. Down-regulation of urokinase 
secretion from a human lymphoma cell line RC-K8 by dexamethasone without 
inducing plasminogen activator inhibitors. Thromb Res 1992; 65: 311-21. 
18. Kubonishi I, Niiya K, Yamashita M, Yano S, Abe T, Ohtsuki Y, Miyoshi I. 
Characterization of a new human lymphoma cell line (RC-K8) with t(11;14) 
chromosome abnormality. Cancer 1986; 58: 1453-60. 
19. Shinbo M, Niiya K, Al-mokdad M, Hayakawa Y, Hiraga K, Fujimaki M, 
Sakuragawa N. Protein kinase activity-dependent inhibition of urokinase-type 
plasminogen activator gene transcription by cycHc AMP in human pre-B lymphoma 
cell line RC-K8. Biochim Biophys Acta 1995: 1268: 293-99. 
20. Degen JL, Estensen RD, Nagamine Y, Re:ich E. Induction and desensitization 
of plasminogen activator gene expression by tumor promoters. J Bioi Chern 1985; 260: 
12426-33. 
21. Canipari R, O'Connell ML, Meyer G, Strickland S. Mouse ovarian granulosa 
cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells 
produce tissue-type plasminogen activator. J Cell Biol 1987; 105: 977-81. 
12 
22. Queenan J Jr., Kao LC, Arboleda CE, Ulloa-Aguirre A, Golos TG, Cines DB, 
Strauss J3. Regulation of urokinase-type plasminogen activator production by cultured 
human cytotrophoblasts. J Biol Chern 1987; 262: 10903-6. 
23. Mira-y-Lopez R. Retinoic acid priming potentiates the induction of urokinase­
type plasminogen activator by cyclic adenosine n1onophosphate in mouse mammary 
carcinoma cells. J Cell Physiol 1991; 147: 46-54. 
24. Takeuchi T, Niiya K, Kubonishi I, Miyoshi I. A plasminogen activator 
inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy­
terminal chain of plasminogen activators. Thromb Haemost 1990; 63: 259-64. 
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-
63. 
26. Pearson D, Nigg EA, Nagamine Y, Jans DA, Hemmings BA. Mechanisms of 
cAMP-mediated gene induction: examination of renal epithelial cell mutants affected in 
the catalytic subunit of the cAMP-dependent protdn kinase. Exp Cell Res 1991; 192: 
315-8. 
27. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor 
complexes in biological fluids. J Exp Med 1978; 148: 223-34. 
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-
9. 
29. Sambrook J, Fritsh EF, Maniatis T. Molecular Cloning, A Laboratory Manual 
2nd Ed. (2nd Ed. ed.) Cold Spring Harber Laboratory, 1989:p 7.39. 
30. White WF, Barlow GH, Mozen MM. Th1� isolation and characterization of 
plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-9. 
31. Jans DA, Hemmings BA. LLC-PK1 cell mutants in cAMP metabolism respond 
normally to phorbol esters. FEBS Lett 1986; 205: 127-31. 
32. Rondeau E, Ochi S, Lacave R, He CJ, Medcalf R, Delarue F, Sraer JD. 
Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 
1989; 36: 593-600. 
33. Medcalf RL. Cell- and gene-specific interactions between signal transduction 
pathways revealed by okadaic acid. Studies on the plasminogen activating system. J 
Bioi Chern 1992; 267: 12220-6. 
34. von der Ahe D, Pearson D, Nagamine Y. Macromolecular interaction on a 
cAMP responsive region in the urokinase-type plasminogen activator gene: a role of 
protein phosphorylation. Nucleic Acids Res. 1990; 18: 1991-9. 
35. Ziegler A, Knesel J, Fabbro D, Nagamine Y. Protein kinase C down-regulation 
enhances cAMP-mediated induction of urokinase-type plasminogen activator mRNA in 
LLC-PK1 cells. J Bioi Chern 1991; 266: 21067-74. 
36. Foulkes NS, Borrelli E, Sassone-Corsi P. CREM gene: use of alternative DNA­
binding domains generates multiple antagonists of cAMP-induced transcription. Cell 
1991; 64: 739-49. 
14 
37. Hayashi T, Niiya K, Hirakawa S, Sakuragawa N. Synergistic stimulating effect 
between cyclic AMP and phorbol ester on plasrninogen activator inhibitor type 2 
production in human promyelocytic leukemia cell line PL-21. Biochim Biophys Acta 
1992; 1134: 273-7. 
38. Niiya K, Taniguchi T, Shinbo M, Ishikawa T, Tazawa S, Hayakawa Y, 
Sakuragawa N. Different regulation of plasminogen activator inhibitor 2 gene 
expression by phorbol ester and cAMP in human myeloid leukemia cell line PL-21. 
Thromb Haemost 1994; 72: 92-7. 
Figure Legends 
Fig. 1 Effect of Beraprost on uP A accumulation in RC-K8 conditioned medium. Cells 
\Vere cultured in the presence of various concentrations of Beraprost (0.1-1000 nM) for 
48 h, and PA activities in the conditioned medium were measured using S-2444. Lane 
1, control; 2, 0.1 nM Beraprost; 3, 1.0 nM; 4, 10 nM; 5, 100 nM; 6, 1000 nM. Results 
are the mean ± SE of 3 determinations. *P<0.05; * *P<0.01 compared with control 
values. 
Fig. 2 Fibrin zymography of conditioned media from Beraprost-treated RC-K8 cells. 
Cells were cultured in the presence of various concentrations of Beraprost (0.1-1 000 
nM) for 48 h. Twenty fLL of the conditioned medim:n was subjected to SDS-PAGE and 
zymography was performed. High (50-54 kDa) and low molecular forms (34 kDa) of 
uP A were observed in the standard uP A preparation and RC-K8 conditioned medium. 
Fig. 3 Dose- and Time-dependent PKA activation by Beraprost. RC-K8 cells were 
cultured in RPMI-1640 containing various concentrations of Beraprost for 10 min in 
panel A and 100 nM Beraprost for indicated times shown in panel B. PKA activities in 
cell lysates were measured as described in Materials and Methods. The mean± SE of 
triplicate values are shown. 
Fig. 4 Time course of uP A mRNA modulation by Beraprost. The autoradiograph 
shown is representative of 3 Northern blot analyses. The blot was first hybridized with 
a uP A eDNA probe and subsequently hybridized with a �-action eDNA probe to 
control for RNA loading. 
Fig. 5 Inhibitory effect of Beraprost on PMA-induced uP A gene expression in RC-K8 
cells. Shown is a representative autoradiograph of ]�orthern blots of uP A and �-actin 5 
16 
hours after treatment with either 100 nM Beraprost (lane 2), 1 ,uM PMA (lane 3) or 
both (lane 4). 
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